CenterBook Partners LP Acquires Shares of 159,421 Definium Therapeutics, Inc. $DFTX

CenterBook Partners LP bought a new position in Definium Therapeutics, Inc. (NASDAQ:DFTX) in the third quarter, HoldingsChannel reports. The fund bought 159,421 shares of the company’s stock, valued at approximately $1,880,000.

A number of other hedge funds have also modified their holdings of the stock. Marshall Wace LLP raised its holdings in shares of Definium Therapeutics by 31.9% during the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after acquiring an additional 828,067 shares in the last quarter. Commodore Capital LP raised its stake in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of Definium Therapeutics during the 2nd quarter valued at about $1,029,000. Finally, Stempoint Capital LP bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $590,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Definium Therapeutics

In other news, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the completion of the transaction, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. The trade was a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 42,667 shares of company stock worth $561,071 in the last ninety days. 2.26% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DFTX. JonesTrading started coverage on shares of Definium Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Finally, Canaccord Genuity Group upped their price target on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and an average target price of $35.22.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $17.27 on Friday. Definium Therapeutics, Inc. has a 12 month low of $4.70 and a 12 month high of $18.70. The company has a market cap of $1.70 billion, a P/E ratio of -8.47 and a beta of 2.57. The business’s 50 day moving average is $15.07 and its two-hundred day moving average is $12.49. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.